Quarterly
Annual
| Unit: USD | 2025-09-28 | 2025-06-29 | 2025-03-30 | 2024-12-31 | 2024-09-29 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-10-01 | 2023-07-02 | 2023-04-02 | 2022-12-31 | 2022-10-02 | 2022-07-03 | 2022-04-03 | 2021-12-31 | 2021-10-03 | 2021-07-04 | 2021-04-04 | 2020-12-31 | 2020-09-27 | 2020-06-28 | 2020-03-29 | 2019-09-29 | 2019-06-30 | 2019-03-31 | 2018-09-30 | 2018-07-01 | 2018-04-01 | 2017-10-01 | 2017-07-02 | 2017-04-02 | 2016-10-02 | 2016-07-03 | 2016-04-03 | 2015-09-27 | 2015-06-28 | 2015-03-29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenues: | ||||||||||||||||||||||||||||||||||||||
product revenues | 13,920,000,000 | 11,954,000,000 | 11,294,000,000 | 15,085,000,000 | 15,417,000,000 | 10,871,000,000 | 12,443,000,000 | |||||||||||||||||||||||||||||||
alliance revenues | 2,298,000,000 | 2,273,000,000 | 2,113,000,000 | 2,248,000,000 | 1,900,000,000 | 2,067,000,000 | 2,172,000,000 | |||||||||||||||||||||||||||||||
royalty revenues | 436,000,000 | 426,000,000 | 308,000,000 | 431,000,000 | 384,000,000 | 345,000,000 | 263,000,000 | |||||||||||||||||||||||||||||||
total revenues | 16,654,000,000 | 14,653,000,000 | 13,715,000,000 | 17,763,000,000 | 17,702,000,000 | 13,283,000,000 | 14,879,000,000 | 14,249,000,000 | 13,232,000,000 | 12,734,000,000 | 18,282,000,000 | 24,290,000,000 | 22,638,000,000 | 27,742,000,000 | 25,661,000,000 | 23,635,000,000 | 24,094,000,000 | 18,977,000,000 | 14,582,000,000 | 5,947,000,000 | 12,131,000,000 | 11,801,000,000 | 12,028,000,000 | 12,680,000,000 | 13,264,000,000 | 13,118,000,000 | 13,298,000,000 | 13,466,000,000 | 12,906,000,000 | 13,168,000,000 | 12,896,000,000 | 12,779,000,000 | 13,045,000,000 | 13,147,000,000 | 13,005,000,000 | 12,087,000,000 | 11,853,000,000 | 10,864,000,000 |
yoy | -5.92% | 10.31% | -7.82% | 24.66% | 33.78% | 4.31% | -18.61% | -41.34% | -41.55% | -54.10% | -28.76% | 2.77% | -6.04% | 46.19% | 75.98% | 297.43% | 98.62% | 60.81% | 21.23% | -53.10% | -8.54% | -10.04% | -9.55% | -5.84% | 2.77% | -0.38% | 3.12% | 5.38% | -1.07% | 0.16% | -0.84% | 5.73% | 10.06% | 21.01% | ||||
qoq | 13.66% | 6.84% | -22.79% | 0.34% | 33.27% | -10.73% | 4.42% | 7.69% | 3.91% | -30.35% | -24.73% | 7.30% | -18.40% | 8.11% | 8.57% | -1.91% | 26.96% | 30.14% | 145.20% | -50.98% | 2.80% | -1.89% | -5.14% | -4.40% | 1.11% | -1.35% | -1.25% | 4.34% | -1.99% | 2.11% | 0.92% | -2.04% | -0.78% | 1.09% | 7.59% | 1.97% | 9.10% | |
costs and expenses: | ||||||||||||||||||||||||||||||||||||||
cost of sales | 4,172,000,000 | 3,778,000,000 | 2,845,000,000 | 5,909,000,000 | 5,263,000,000 | 3,300,000,000 | 3,379,000,000 | 7,563,000,000 | 9,269,000,000 | 3,237,000,000 | 4,886,000,000 | 9,648,000,000 | 6,063,000,000 | 8,648,000,000 | 9,984,000,000 | 9,589,000,000 | 9,973,000,000 | 7,049,000,000 | 4,211,000,000 | 1,504,000,000 | 2,529,000,000 | 2,281,000,000 | 2,378,000,000 | 2,602,000,000 | 2,576,000,000 | 2,433,000,000 | 2,694,000,000 | 2,916,000,000 | 2,563,000,000 | 2,847,000,000 | 2,663,000,000 | 2,470,000,000 | 3,085,000,000 | 3,174,000,000 | 2,851,000,000 | 2,219,000,000 | 2,180,000,000 | 1,838,000,000 |
gross profit | 12,482,000,000 | 10,875,000,000 | 10,870,000,000 | 11,854,000,000 | 12,439,000,000 | 9,983,000,000 | 11,500,000,000 | 6,686,000,000 | 3,963,000,000 | 9,497,000,000 | 13,396,000,000 | 14,642,000,000 | 16,575,000,000 | 19,094,000,000 | 15,677,000,000 | 14,046,000,000 | 14,121,000,000 | 11,928,000,000 | 10,371,000,000 | 4,443,000,000 | 9,602,000,000 | 9,520,000,000 | 9,650,000,000 | 10,078,000,000 | 10,688,000,000 | 10,685,000,000 | 10,604,000,000 | 10,550,000,000 | 10,343,000,000 | 10,321,000,000 | 10,233,000,000 | 10,309,000,000 | 9,960,000,000 | 9,973,000,000 | 10,154,000,000 | 9,868,000,000 | 9,673,000,000 | 9,026,000,000 |
yoy | 0.35% | 8.94% | -5.48% | 77.30% | 213.88% | 5.12% | -14.15% | -54.34% | -76.09% | -50.26% | -14.55% | 4.24% | 17.38% | 60.08% | 51.16% | 216.14% | 47.06% | 25.29% | 7.47% | -55.91% | -10.16% | -10.90% | -9.00% | -4.47% | 3.34% | 3.53% | 3.63% | 2.34% | 3.85% | 3.49% | 0.78% | 4.47% | 2.97% | 10.49% | ||||
qoq | 14.78% | 0.05% | -8.30% | -4.70% | 24.60% | -13.19% | 72.00% | 68.71% | -58.27% | -29.11% | -8.51% | -11.66% | -13.19% | 21.80% | 11.61% | -0.53% | 18.39% | 15.01% | 133.42% | -53.73% | 0.86% | -1.35% | -4.25% | -5.71% | 0.03% | 0.76% | 0.51% | 2.00% | 0.21% | 0.86% | -0.74% | 3.50% | -0.13% | -1.78% | 2.90% | 2.02% | 7.17% | |
gross margin % | 74.95% | 74.22% | 79.26% | 66.73% | 70.27% | 75.16% | 77.29% | 46.92% | 29.95% | 74.58% | 73.27% | 60.28% | 73.22% | 68.83% | 61.09% | 59.43% | 58.61% | 62.86% | 71.12% | 74.71% | 79.15% | 80.67% | 80.23% | 79.48% | 80.58% | 81.45% | 79.74% | 78.35% | 80.14% | 78.38% | 79.35% | 80.67% | 76.35% | 75.86% | 78.08% | 81.64% | 81.61% | 83.08% |
selling, informational and administrative expenses | 3,186,000,000 | 3,415,000,000 | 3,031,000,000 | 4,274,000,000 | 3,244,000,000 | 3,717,000,000 | 3,495,000,000 | 4,575,000,000 | 3,281,000,000 | 3,497,000,000 | 3,418,000,000 | 4,645,000,000 | 3,391,000,000 | 3,048,000,000 | 2,593,000,000 | 4,086,000,000 | 2,905,000,000 | 2,928,000,000 | 2,783,000,000 | 2,696,000,000 | 3,016,000,000 | 3,030,000,000 | 2,873,000,000 | 3,260,000,000 | 3,511,000,000 | 3,339,000,000 | 3,494,000,000 | 3,542,000,000 | 3,412,000,000 | 3,500,000,000 | 3,425,000,000 | 3,308,000,000 | 3,559,000,000 | 3,471,000,000 | 3,385,000,000 | 3,270,000,000 | 3,386,000,000 | 3,104,000,000 |
research and development expenses | 2,546,000,000 | 2,482,000,000 | 2,203,000,000 | 3,035,000,000 | 2,598,000,000 | 2,696,000,000 | 2,493,000,000 | 2,815,000,000 | 2,711,000,000 | 2,648,000,000 | 2,505,000,000 | 3,615,000,000 | 2,696,000,000 | 2,815,000,000 | 2,301,000,000 | 5,909,000,000 | 3,447,000,000 | 2,459,000,000 | 2,014,000,000 | 3,189,000,000 | 2,360,000,000 | 2,132,000,000 | 1,724,000,000 | 2,283,000,000 | 1,842,000,000 | 1,703,000,000 | 2,008,000,000 | 1,797,000,000 | 1,743,000,000 | 1,859,000,000 | 1,780,000,000 | 1,708,000,000 | 1,881,000,000 | 1,748,000,000 | 1,731,000,000 | 1,722,000,000 | 1,734,000,000 | 1,885,000,000 |
acquired in-process research and development expenses | 1,390,000,000 | 2,000,000 | 9,000,000 | 88,000,000 | 13,000,000 | 6,000,000 | 72,000,000 | 67,000,000 | 33,000,000 | 21,000,000 | 73,000,000 | 524,000,000 | 1,000,000 | 355,000,000 | ||||||||||||||||||||||||
amortization of intangible assets | 1,223,000,000 | 1,211,000,000 | 1,211,000,000 | 1,359,000,000 | 1,312,000,000 | 1,307,000,000 | 1,308,000,000 | 1,267,000,000 | 1,179,000,000 | 1,184,000,000 | 1,103,000,000 | 1,131,000,000 | 822,000,000 | 822,000,000 | 835,000,000 | 916,000,000 | 981,000,000 | 931,000,000 | 872,000,000 | 748,000,000 | 898,000,000 | 905,000,000 | 885,000,000 | 1,212,000,000 | 1,184,000,000 | 1,183,000,000 | 1,253,000,000 | 1,191,000,000 | 1,196,000,000 | 1,177,000,000 | 1,208,000,000 | 1,186,000,000 | 968,000,000 | 961,000,000 | 1,006,000,000 | 937,000,000 | 872,000,000 | 940,000,000 |
restructuring charges and certain acquisition-related costs | 286,000,000 | -18,000,000 | 678,000,000 | 750,000,000 | 313,000,000 | 1,254,000,000 | 102,000,000 | 2,566,000,000 | 155,000,000 | 214,000,000 | 9,000,000 | 795,000,000 | 199,000,000 | 189,000,000 | 192,000,000 | 134,000,000 | 646,000,000 | -1,000,000 | 23,000,000 | 165,000,000 | 4,000,000 | 362,000,000 | 69,000,000 | 365,000,000 | 46,000,000 | 85,000,000 | 44,000,000 | 43,000,000 | 149,000,000 | 70,000,000 | 157,000,000 | 531,000,000 | 316,000,000 | 141,000,000 | 581,000,000 | 86,000,000 | 60,000,000 | |
other (income)/deductions––net | 517,000,000 | 739,000,000 | 953,000,000 | 2,358,000,000 | 243,000,000 | 1,107,000,000 | 680,000,000 | -479,000,000 | -79,000,000 | -347,000,000 | 70,000,000 | -846,000,000 | -59,000,000 | 772,000,000 | 350,000,000 | -1,181,000,000 | -1,696,000,000 | -998,000,000 | -1,004,000,000 | 162,000,000 | 1,148,000,000 | 221,000,000 | 319,000,000 | 126,000,000 | 92,000,000 | 51,000,000 | 1,417,000,000 | 1,068,000,000 | 330,000,000 | 661,000,000 | 55,000,000 | |||||||
income from continuing operations before provision/(benefit) for taxes on income | 3,334,000,000 | 2,785,000,000 | 3,421,000,000 | 2,269,000,000 | 6,270,000,000 | 5,231,000,000 | 9,001,000,000 | 11,447,000,000 | 9,050,000,000 | 4,183,000,000 | 7,836,000,000 | -2,517,000,000 | 2,176,000,000 | 3,953,000,000 | 4,141,000,000 | |||||||||||||||||||||||
provision/(benefit) for taxes on income | -216,000,000 | -189,000,000 | 293,000,000 | -71,000,000 | 715,000,000 | 230,000,000 | 356,000,000 | 1,570,000,000 | 1,172,000,000 | 334,000,000 | -331,000,000 | -491,000,000 | -26,000,000 | 519,000,000 | ||||||||||||||||||||||||
income from continuing operations | 3,550,000,000 | 2,903,000,000 | 2,973,000,000 | 31,000,000 | 3,128,000,000 | 2,340,000,000 | 5,555,000,000 | 5,001,000,000 | 8,645,000,000 | 9,877,000,000 | 7,879,000,000 | 3,849,000,000 | 8,167,000,000 | 5,565,000,000 | 4,877,000,000 | -2,025,000,000 | 2,202,000,000 | 3,434,000,000 | 3,410,000,000 | 7,680,000,000 | 5,056,000,000 | 3,889,000,000 | 4,111,000,000 | 3,879,000,000 | 3,571,000,000 | 2,858,000,000 | 3,077,000,000 | 3,130,000,000 | 1,320,000,000 | 2,035,000,000 | 3,026,000,000 | 2,130,000,000 | 2,635,000,000 | 2,376,000,000 | ||||
discontinued operations––net of tax | 25,000,000 | 7,000,000 | -8,000,000 | 17,000,000 | -5,000,000 | -26,000,000 | 12,000,000 | -2,000,000 | 1,000,000 | 2,000,000 | -21,000,000 | 34,000,000 | -9,000,000 | 4,000,000 | 11,000,000 | 2,000,000 | 1,000,000 | 8,000,000 | 1,000,000 | 5,000,000 | ||||||||||||||||||
net income before allocation to noncontrolling interests | 3,550,000,000 | 2,928,000,000 | 2,973,000,000 | 48,000,000 | 3,123,000,000 | 2,338,000,000 | 5,556,000,000 | 5,003,000,000 | 8,623,000,000 | 9,911,000,000 | 7,870,000,000 | 3,392,000,000 | 8,159,000,000 | 5,589,000,000 | 4,886,000,000 | 606,000,000 | 2,202,000,000 | 3,434,000,000 | 3,410,000,000 | 7,684,000,000 | 5,056,000,000 | 3,889,000,000 | 4,122,000,000 | 3,879,000,000 | 3,570,000,000 | 2,858,000,000 | 3,078,000,000 | 3,130,000,000 | 1,319,000,000 | 2,035,000,000 | 3,026,000,000 | 2,139,000,000 | 2,635,000,000 | 2,381,000,000 | ||||
less: net income attributable to noncontrolling interests | 9,000,000 | 18,000,000 | 6,000,000 | 8,000,000 | 8,000,000 | 7,000,000 | 8,000,000 | 9,000,000 | 6,000,000 | 11,000,000 | 13,000,000 | 8,000,000 | 15,000,000 | 6,000,000 | 6,000,000 | -2,000,000 | 12,000,000 | 26,000,000 | 9,000,000 | 11,000,000 | 8,000,000 | 8,000,000 | 9,000,000 | 4,000,000 | 10,000,000 | 6,000,000 | 8,000,000 | 7,000,000 | 9,000,000 | 18,000,000 | 5,000,000 | 9,000,000 | 16,000,000 | 9,000,000 | 9,000,000 | 9,000,000 | 6,000,000 | |
net income attributable to pfizer inc. common shareholders | 3,541,000,000 | 2,910,000,000 | 2,967,000,000 | 41,000,000 | 3,115,000,000 | 2,327,000,000 | 5,543,000,000 | 4,994,000,000 | 8,608,000,000 | 9,906,000,000 | 7,864,000,000 | 3,393,000,000 | 8,146,000,000 | 5,563,000,000 | 4,877,000,000 | 9,614,380,000 | 390,000 | 620,000 | 610,000 | 1,380,000 | 910,000 | 690,000 | 700,000 | 660,000 | 600,000 | 480,000 | 520,000 | 520,000 | 220,000 | 330,000 | 490,000 | 350,000 | 430,000 | 380,000 | ||||
earnings per common share––basic: | ||||||||||||||||||||||||||||||||||||||
income from continuing operations attributable to pfizer inc. common shareholders | 620,000 | 510,000 | 520,000 | 10,000 | 550,000 | 410,000 | 980,000 | 890,000 | 1,540,000 | 1,760,000 | 1,400,000 | 680,000 | 1,450,000 | 990,000 | 870,000 | -360,000 | 390,000 | 620,000 | 610,000 | 1,380,000 | 910,000 | 690,000 | 700,000 | 660,000 | 600,000 | 480,000 | 520,000 | 520,000 | 220,000 | 330,000 | 490,000 | 340,000 | 430,000 | 380,000 | ||||
earnings per common share––diluted: | ||||||||||||||||||||||||||||||||||||||
weighted-average shares––basic | 5,685,000,000 | 5,685,000,000 | 5,675,000,000 | 5,664,000,000 | 5,667,000,000 | 5,666,000,000 | 5,657,000,000 | 5,643,000,000 | 5,646,000,000 | 5,646,000,000 | 5,634,000,000 | 5,608,000,000 | 5,607,000,000 | 5,593,000,000 | 5,617,000,000 | 5,601,000,000 | 5,609,000,000 | 5,598,000,000 | 5,584,000,000 | 5,555,000,000 | 5,557,000,000 | 5,554,000,000 | 5,545,000,000 | 5,545,000,000 | 5,562,000,000 | 5,635,000,000 | 5,875,000,000 | 5,866,000,000 | 5,957,000,000 | 5,951,000,000 | 5,958,000,000 | 6,006,000,000 | 6,066,000,000 | 6,068,000,000 | 6,150,000,000 | 6,168,000,000 | 6,159,000,000 | 6,203,000,000 |
weighted-average shares––diluted | 5,714,000,000 | 5,706,000,000 | 5,710,000,000 | 5,700,000,000 | 5,705,000,000 | 5,696,000,000 | 5,697,000,000 | 5,709,000,000 | 5,646,000,000 | 5,713,000,000 | 5,727,000,000 | 5,733,000,000 | 5,718,000,000 | 5,712,000,000 | 5,758,000,000 | 5,708,000,000 | 5,725,000,000 | 5,678,000,000 | 5,662,000,000 | 5,632,000,000 | 5,633,000,000 | 5,619,000,000 | 5,613,000,000 | 5,649,000,000 | 5,672,000,000 | 5,750,000,000 | 5,986,000,000 | 5,952,000,000 | 6,057,000,000 | 6,041,000,000 | 6,037,000,000 | 6,092,000,000 | 6,138,000,000 | 6,137,000,000 | 6,214,000,000 | 6,243,000,000 | 6,243,000,000 | 6,292,000,000 |
income/ | 3,044,000,000 | 2,008,250,000 | 4,715,000,000 | -103,000,000 | 1,296,750,000 | -3,352,000,000 | ||||||||||||||||||||||||||||||||
provision/ | 141,000,000 | 98,250,000 | 234,000,000 | -134,000,000 | -80,000,000 | -964,000,000 | ||||||||||||||||||||||||||||||||
income/(loss) from continuing operations | 1,910,000,000 | 4,481,000,000 | 1,376,750,000 | -2,388,000,000 | ||||||||||||||||||||||||||||||||||
net income/(loss) before allocation to noncontrolling interests | 1,911,000,000 | 4,473,000,000 | 1,379,500,000 | -2,376,000,000 | ||||||||||||||||||||||||||||||||||
net income/(loss) attributable to pfizer inc. common shareholders | 1,905,250,000 | 4,465,000,000 | 1,372,000,000 | -2,382,000,000 | ||||||||||||||||||||||||||||||||||
earnings/(loss) per common share––basic: | ||||||||||||||||||||||||||||||||||||||
income/(loss) from continuing operations attributable to pfizer inc. common shareholders | 337,500 | 790,000 | 242,500 | -420,000 | ||||||||||||||||||||||||||||||||||
earnings/(loss) per common share––diluted: | ||||||||||||||||||||||||||||||||||||||
(gain) on completion of consumer healthcare jv transaction | ||||||||||||||||||||||||||||||||||||||
income/(loss) from discontinued operations––net of tax | 6,000,000 | -9,000,000 | ||||||||||||||||||||||||||||||||||||
income from continuing operations before benefit from taxes on income | 6,609,000,000 | 5,683,000,000 | 3,885,000,000 | 10,727,000,000 | 4,323,000,000 | 4,177,000,000 | 4,527,000,000 | 4,127,000,000 | 3,585,000,000 | 3,815,000,000 | 3,951,000,000 | 1,604,000,000 | 2,410,000,000 | 3,561,000,000 | 2,697,000,000 | 3,539,000,000 | 3,082,000,000 | |||||||||||||||||||||
benefit from taxes on income | 1,043,000,000 | 805,000,000 | 475,000,000 | 3,047,000,000 | 433,000,000 | 66,000,000 | 648,000,000 | 556,000,000 | 727,000,000 | 739,000,000 | 821,000,000 | 284,000,000 | 375,000,000 | 535,000,000 | 567,000,000 | 905,000,000 | 706,000,000 | |||||||||||||||||||||
income from discontinued operations––net of tax | 24,000,000 | 9,000,000 | ||||||||||||||||||||||||||||||||||||
net income attributable to pfizer inc. | 2,255,500,000 | 2,194,000,000 | 3,426,000,000 | 3,401,000,000 | 7,680,000,000 | 5,046,000,000 | 3,884,000,000 | 4,114,000,000 | 3,872,000,000 | 3,561,000,000 | 2,840,000,000 | 3,073,000,000 | 3,121,000,000 | 1,320,000,000 | 2,019,000,000 | 3,016,000,000 | 2,130,000,000 | 2,626,000,000 | 2,376,000,000 | |||||||||||||||||||
cash dividends paid per common share | 340,000 | 340,000 | 340,000 | 320,000 | 320,000 | 320,000 | 300,000 | 300,000 | 300,000 | 280,000 | 280,000 | 280,000 | ||||||||||||||||||||||||||
earnings per common share––basic | ||||||||||||||||||||||||||||||||||||||
earnings per common share––diluted |
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.